Drawing for FERTIN PHARMA VOYE

USPTO serial 98314922

FERTIN PHARMA VOYE

Reviewed by CopyMark Law Group

Reg. 7710098Status 711
Filing date
Status date
Registration date
Mar 4, 2025
Examiner
BUSH, KAREN K
Law office
Historical data usage

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FERTIN PHARMA VOYE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tamar Niv Bessinger

Tamar Niv Bessinger Fross Zelnick Lehrman & Zissu, P.C.151 W 42nd St 17th FloorNew York, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
005Nicotine gum for use as an aid to stop smokingSECTION 7(e) - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 11, 2026NCS7NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED—
Sep 11, 2026C7..CANCELLED SECTION 7-TOTAL—
Sep 7, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 6, 2026C7RFREQUEST FOR SECT 7 TOTAL SURRENDER FILED—
Jul 6, 2026ES7STEAS SECTION 7 SURRENDER RECEIVED—
Mar 4, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 4, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 14, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 14, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 8, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 23, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 1, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 1, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 1, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 17, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 17, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 15, 2024DOCKASSIGNED TO EXAMINER—
Jun 17, 2024MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Jun 17, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 14, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance